Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Orphan Drugs Aplenty At US FDA, From Pyrukynd Approval To Adagrasib Standard Review

Feb 21 2022

• By Bridget Silverman

Keeping Track Feature image

Related Content

Keeping Track: US FDA Issues Alzheimer’s Breakthrough Designations, Arimoclomol CRL, Rinvoq Delays

Jun 27 2021

Accelerated Approval Roadblock: Agenus’ PD-1 Stumble Reflects Pathway’s Regulatory Risk

Oct 28 2021

Keeping Track: US FDA Approves Amgen’s Lumakras, Myovant’s Myfembree; New Claims For Biohaven’s Nurtec, BMS’ Zeposia

May 28 2021

When Breakthrough Falls Short: US FDA Complete Response Letters Rising Among BTD Applications For Approval

Jul 21 2021

US FDA’s New Drug Median Review Time Held Steady At Eight Months In 2021

Jan 22 2022

Sanofi Posts More Positive Olipudase Alfa Data As Approval Decisions Loom

Feb 10 2022

Related Companies

Agios Pharmaceuticals, Inc.

Sanofi

Mirati Therapeutics, Inc.

Novartis AG

23andMe, Inc.

Revvity Inc.

Amgen, Inc.

Orphazyme A/S

Additional Topics

Rare Diseases Approvals Drug Review Regulation Drug Approval Standards Review Pathway US FDA Performance Tracker BioPharmaceutical Neurology Cancer

More from Rare Diseases

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window